
Combined VEGF/PD-L1 Inhibition Displays Frontline Efficacy in ES-SCLC
The combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and etoposide elicited frontline efficacy in patients with extensive-stage small cell lung cancer (ES-SCLC), meeting the primary end point of 1-year overall survival (OS) in …